Abbreviations: mTOR (mammalian target of rapamycin) , EGFR (epidermal growth factor receptor), HIF-1 (hypoxia inducible factor-1 -subunit), PI3K (phosphatidylinositol 3'-kinase), FCS (fetal calf serum), PBS (phosphate buffered saline) Abstract Esophageal squamous cell carcinoma (ESCC) remains one of the most aggressive cancers with poor prognosis regardless of a several reports that indicate a better therapeutic efficacy using some new chemotherapeutic agents. Recent drug development has contributed to an improved specificity to suppress mTOR activity by which many types of malignancies can be explosively progressed. Temsirolimus (CCI-779, TricelTM) is one of recently synthesized analogues of rapamycin and has provided better outcomes for patients with renal cell carcinoma. In this study, we experimentally evaluated an efficacy of targeting mTOR by temsirolimus for ESCC treatment, with an assessment of its survival advantage using an advanced ESCC animal model. First, we confirmed that the expression of phosphorylated mTOR was increased in 46 of 58 clinical ESCC tumor tissues (79.3%) and appeared to get strengthened with tumor progression. All of ESCC cell lines used in this study revealed an increase of mTOR phosphorylation, accompanied with the upregulation of hypoxia inducible factor-I alpha (HIF-1α), one of the critical effectors regulated by mTOR. Temsirolimus treatment apparently suppressed the activation of mTOR and its downstream effectors, resulting in the reduced ability of ESCC cell proliferation.
Introduction
Esophageal cancer is an aggressive malignancy with poor prognosis. 1 Pathologically, it mainly consists of adenocarcinoma and squamous cell carcinoma, the former often occurs in Western countries, whereas the latter predominates in Asia. 2 The surest current therapy for esophageal cancer is surgical treatment.
However, we often find both types of esophageal cancer at an advanced stage, resulting in the consideration of a combination therapy with both surgical and non-surgical treatments. Squamous cell carcinoma of the esophagus is relatively susceptible to many kinds of new medicine for chemotherapy that have been developed and introduced in clinical practice, but the mortality rate has not been improved. 3 Recently, drug development strategy has focused on targeting particular molecules that are supposedly critical for cancer progression. Several molecules in growth factor receptor pathways are preferentially employed for specific targeting since those molecules are well recognized as being aberrantly regulated in cancers.
For example, epidermal growth factor receptor (EGFR) and its downstream pathway are often upregulated due to gene amplification or mutation 4 , and therefore targeting EGFR is a major therapeutic strategy for cancer treatment.
However, in some cases these drugs only show a minimal effectiveness due to the 6 aberrant regulation of downstream molecules located beneath the receptor tyrosine kinase pathways such as Ras-Raf-MAPK and phosphatidylinositol 3'-kinase (PI3K)-Akt. [5] [6] [7] [8] Among these downstream molecules, mammalian target of rapamycin (mTOR) is one of the major effectors regulated by the PI3K-Akt signaling pathway and plays a central role in this stimulated growth and survival signaling. 9, 10 Therefore, several compounds that selectively inhibit mTOR activity have been developed for clinical use. 11, 12 Temsirolimus (CCI-779, Tricel TM ), an analogue of rapamycin, was recently synthesized to specifically inhibit mTOR and has provided better outcomes for patients with renal cell carcinoma. 13 It was also reported that temsirolimus showed an antitumor effect on other types of cancer including breast cancer, 14 glioblastoma, 15 neuroendocrine carcinomas, 16 and mantle cell lymphoma. 17 Based upon this evidence, we questioned whether temsirolimus treatment could be a good alternative strategy for ESCC. In this study, we evaluated the antiproliferative and antitumor effects of temsirolimus on ESCC in vitro and in vivo, with an assessment of its survival advantage in an advanced ESCC animal model.
Results
The activities of mTOR and its downstream molecules are upregulated in esophageal squamous cell carcinoma.
First, the expression status of mTOR and phosphorylated mTOR in surgically resected tissues of esophageal squamous cell carcinoma was examined by immunohistochemistry. The expression of mTOR was equally detected both in normal esophageal epithelia and in cancer tissues ( Figure 1A , upper panels). The expression of phosphorylated mTOR was also detected in the cytoplasm of cancer tissues while its intensity in normal esophageal epithelia was very faint ( Figure 1A , left lower panel). Of note, the phosphorylated mTOR was highly expressed at the edge of the tumors ( Figure 1A , right lower panel). Progressive cancer cases tended to have a poor prognosis, and the intensity of p-mTOR expression became high in aggressive cases ( Figure 1B ).
Immunohistochemistry was also performed to evaluate the expressions of mTOR and phosphorylated mTOR in cultured cells. As shown in Figure 2A , the expression of mTOR was detected in esophageal cancer cells (TE-1, TE-8, and TE-10) as well as in KOB9N and KOB12N cells, both of which were primary esophageal epithelial cells that were isolated from surgically resected human esophageal tissues. 18 KOB9N and KOB9C cells, which were isolated from the surgically resected esophageal epithelia and tumor tissues of a single esophageal cancer patient, respectively, were used to compare the expression status of mTOR and phosphorylated mTOR to each other ( Figure 2A ). Interestingly, both showed a similar expression of mTOR, while the intensity of phosphorylated mTOR in the cancer cells (KOB9C) was definitely stronger than in the normal epithelial cells (KOB9N). Similarly, all of the TE-1, TE-8, and TE-10 cells showed a higher intensity of phosphorylated mTOR than the normal esophageal epithelial cells (KOB9N and KOB12N) ( Figure 2A ). These results indicated that mTOR appeared to exist ubiquitously regardless of tissue type, whereas cancer tissues/cells definitely increased the mTOR activity.
The activation of mTOR is known to positively regulate protein translation and cell proliferation by upregulating downstream molecules such as hypoxia inducible factor-1 -subunit (HIF-1 ), 21 Figure 2B ). This suggests that the upregulation of downstream molecules such as HIF-paralleled that of mTOR, leading to the idea that targeting mTOR activity can be a potential therapeutic strategy for esophageal squamous cell carcinoma.
A selective mTOR inhibitor, temsirolimus, reveals an antiproliferative effect in esophageal cancer cells by inhibiting the mTOR pathway.
Using temsirolimus, an analogue of rapamycin that has recently been synthesized as a selective mTOR inhibitor, we aimed to inhibit mTOR activity to evaluate its possible anticancer effects in esophageal cancer cells. After the cancer cells (TE-1, TE-8, and TE-10) were treated with temsirolimus at different concentrations (0-1000nM), the expressions of mTOR and S6, a major downstream molecule, were examined by Western blot. Temsirolimus treatment did not affect the expressions of total mTOR or S6 in esophageal cancer cells, but it significantly reduced the expressions of phosphorylated mTOR and phosphorylated S6 around a concentration of 1nM and the effect was observed in a dose-dependent manner, regardless of cell line ( Figure 3 ). Interestingly, the expression and activity of 4E-BP1, another downstream molecule of the mTOR pathway, did not change after temsirolimus treatment ( Figure 3 ).
Next, we assessed the effect of mTOR inhibition from temsirolimus on cell proliferation in esophageal cancer cells. When the cancer cells were treated with temsirolimus at different concentrations (0-1000nM), their growth was dose-dependently suppressed ( Figure 4 ). These results indicated that the inhibition of the mTOR pathway by temsirolimus negatively affected the growth of esophageal cancer cells, and that targeting mTOR can be a potential alternative for esophageal cancer treatment.
Temsirolimus provides a survival advantage to tumor-bearing mice by retarding tumor growth.
To clarify the potential effectiveness of temisrolimus for esophageal cancer treatment, we applied this selective mTOR inhibitor to animal experiments. An intravenous administration of temsirolimus was given to mice with subcutaneous tumors of TE-8 cells according to the schedule described in the Materials and Methods section and the tumor volume was measured once a week. The growth of the subcutaneous tumors was significantly reduced by temsirolimus treatment in a dose-dependent manner ( Figure 5A ). On day 28, the mice treated with 10mg/kg of temsirolimus had an approximately 6-fold less tumor volume than the control (vehicle only) mice (vehicle: 3261.6 ± 722.0, temsirolimus: 599.2 ± 122.9; p=0.007).
During the observation period the body weight of each mouse was tracked as a surrogate marker of drug toxicity and we observed no significant differences in body weight between the groups (data not shown).
Furthermore, we applied a similar treatment with temsirolimus to an orthotopic esophageal cancer model that was recently established. 19 As shown previously, this orthotopic mouse model shows a quick outcome from a lack of food intake due to esophageal stricture by the orthotopic tumor. Thus, we hypothesized that the inhibition of orthotopic tumor growth by temsirolimus would prolong the survival of this mouse model if the esophageal stricture could be retarded and normal food intake maintained. An intraperitoneal administration of temsirolimus or PBS as a vehicle was given to the mice with an orthotopic esophageal tumor once a week, and their survival was tracked ( Figure 5B ). The mice with temsirolimus treatment significantly extended their survival compared to the control mice (median survival periods; control: 31 days, temsirolimus: 43 days; p=0.0024).
These results support our idea that the inhibition of mTOR could provide a survival advantage for advanced esophageal cancer patients, and therefore, we propose that temsirolimus might be a potential alternative strategy for esophageal cancer treatment.
Discussion
Recent cancer therapy studies have been paying close attention to the key molecules of the signaling pathways that are important for cell migration, proliferation, progression and the invasion of tumors. mTOR is one of the molecules associated with basic biological processes such as the signal transduction of cell proliferation, migration, angiogenesis, and synthesis of tumorigenic proteins. In addition to its role as a basic controller in organisms, mTOR is also known to be involved in tumor progression. 22 Aberrant PI3K-dependent signaling and protein translation may contribute to the development and progression of human cancers.
Activation mutations of growth factor receptors and PI3K, as well as the amplification and/or overexpression of PI3K and Akt have been reported in different types of malignancies. 23 If cancer cell growth and survival is dependent on the PI3K-Akt pathway, it is possible that this dependency in cancer cells would result in increased sensitivity to mTOR inhibitors.
In in vitro studies, it was revealed that mTOR is activated in esophageal squamous cell carcinoma cell lines and that mTOR expression is inhibited by rapamycin. 21 There is an immunohistochemical study in which activated mTOR was detected in one-quarter of esophageal squamous cell carcinoma tissues. 24 Our data in this study showed that the expression of phosphorylated mTOR was significantly higher in cancer tissues than in normal esophageal epithelia. In addition, the expression tended to be concentrated at the invasive front of tumors. This may suggest that intense tumor proliferation and progression may largely rely on a strong activation of mTOR signaling in esophageal cancer. Thus, it makes sense to apply mTOR inhibition to esophageal cancer treatment, and we believe that at least a certain population of esophageal cancer patients may potentially benefit from this therapy.
Hou G. et al. reported that the mTOR-p70S6K pathway is activated in esophageal squamous cell carcinoma and that rapamycin and siRNA rapidly inhibited the expression of mTOR and the phosphorylation of its major downstream effectors, p70S6K and 4E-BP1. 25 They also reported that the inhibition of mTOR induced G0/G1 cell cycle arrest and apoptosis of esophageal squamous cell carcinoma cells. In our study, temsirolimus, an analogue of rapamycin, suppressed the phosphorylation of mTOR and S6 at a concentration of 1nM in all of the tested esophageal cancer cell lines. Interestingly, 4E-BP1, another downstream molecule beneath mTOR, was not affected by this treatment in our experiments (Figure 3) .
Moreover, our observation by cell cycle analysis and TUNEL assay did not show any apparent cell death or the induction of apoptosis from temsirolimus treatment (data not shown). In general, the inhibition of mTOR downregulates the translation of specific mRNAs that are required for cell cycle progression from the G1 phase to the S phase. 26, 27 Taken together, we speculate that temsirolimus induced the inhibition of cell proliferation with cell accumulation in the G0/G1 phase rather than leading to apoptosis and therefore the intrinsic effect of temsirolimus in human esophageal cancer is cytostatic.
In our study, treatment with a nanomolar level of temsirolimus was enough to suppress the phosphorylation of mTOR and its substrates S6. Shor B. et al.
proved that a low micromolar concentration of temsirolimus completely suppressed the proliferation of a broad panel of tumor cells including lung cancer, colon cancer, breast cancer, and human embryonic kidney cell lines. 28 They hypothesized that the response of tumor cells to the commonly used nanomolar concentrations of rapamycin may be limited by the feedback loop, whereas the suppression of S6 signaling by rapamycin stimulates the IRS-PI3K pathway to promote AKT activity.
Our data did not support their opinion, but further experiments will be needed in the future.
Using our established primary human esophageal epithelial cells and cancer cells, 18 we compared the expression and activation of mTOR and HIF-1 , a downstream molecule affected by the mTOR pathway. Our data that these proteins showed less activity in normal esophageal epithelial cells led us to investigate the tolerance of these normal esophageal cells to an mTOR inhibitor, specifically temsirolimus. This may provide some knowledge to help determine the most effective dose of this drug for cancer therapy. Although we used esophageal squamous cell carcinoma cells in this study, we also recently reported that a dual tyrosine kinase inhibitor for focal adhesion kinase (FAK) and insulin-like growth factor-I receptor (IGF-IR) exhibits anticancer effects in esophageal adenocarcinoma in vitro and in vivo. 29 We also confirmed that this dual tyrosine kinase inhibitor suppressed mTOR activity in esophageal cancer cells. 30 It would be intriguing to evaluate the effectiveness of temsirolimus in esophageal adenocarcinoma in further basic and clinical studies.
In conclusion, we showed the importance of the mTOR signaling pathway on the regulation of cell proliferation in the esophagus and temsirolimus could 16 inhibit the activity of mTOR and its downstream molecule S6. Temsirolimus may be useful for esophageal cancer treatment as a novel therapeutic instrument.
Materials and Methods
Clinical tissues 
Antibodies and Reagents
The following antibodies used in this study were purchased from Cell the working concentrations (0-1000nM) with culture media before use in vitro.
When temsirolimus was used for animal experiments, it was dissolved in attached diluents, and diluted to a final concentration of either 2 mg/kg or 10mg/kg with 0.9% sodium chloride.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections mounted on silanized slides were deparaffinized in xylene for 20 min and rehydrated through a graded ethanol series. Endogenous peroxidase was blocked by incubating the sections in 3.0% H2O2 in methanol for 15 min. Antigen retrieval on the paraffin sections was performed by heating two times in a 10 mM citrate buffer solution (pH 6.0) in a microwave. After blocking nonspecific reactivity with rabbit serum for 10 min at room temperature, sections were incubated overnight at 4°C with the primary antibodies, followed by immuno-bridging with Avidin DH-biotinylated horseradish peroxide complex (Histofine SAB PO kit; Cat.No. 424031; Nichirei, Tokyo, Japan).
Immunostaining was developed using a 3,3'-diaminobenzidine tetrahydrochloride (DAB)/hydrogen peroxidase solution (Histofine DAB substrate kit; Cat.No.415192;
Dako Japan, Tokyo, Japan), and sections were counterstained with Mayer's hematoxylin. Culture cells that were seeded into chamber slides were fixed in 4% paraformaldehyde for 10 min at room temperature, and then were made permeable by treating them with Triton X-100 for 2 min at room temperature before the subsequent incubation step with the antibodies. To prepare an orthotopic esophageal cancer model, we followed a procedure that we recently reported on. 19 . Briefly, a cell suspension of 5x10 6 
Figure 3
The mTOR inhibitor temsirolimus inhibits the activation of mTOR and its downstream molecules in esophageal cancer cells.
Three esophageal cancer cell lines (TE-1, TE-8, and TE-10) were treated with different concentrations of temsirolimus (0-1000nM) and western blot was performed with appropriate antibodies to detect the expression of mTOR and its downstream effectors. β-actin was served as an internal control.
Figure 4
Temsirolimus suppresses cell proliferation of esophageal cancer cells.
Three esophageal cancer cell lines (A: TE-1, B: TE-8, C: TE-10) were treated with different concentrations of temsirolimus (0-1000nM) and the cell number at the indicated time point (day0, 1, 3, and 5) was counted to draw these growth curve.
Figure 5
Administration of temsirolimus reduces tumor growth and prolongs the survival of tumor-bearing mice.
A. Subcutaneous tumor-bearing mice were subgrouped into three groups for intraperitoneal administration of either 2 different doses of temsirolimus (2mg/kg and 10mg/kg) or phosphate buffered saline (PBS) as a control group at the scheduled dates, as described in "Materials and Methods" section. Tumor volume [(length x width 2 ) / 2] was measured to draw a histogram. B.
Orthotopic esophageal cancer-bearing mice were divided into two groups for intraperitoneal administration of either temsirolimus or PBS (control) at the scheduled dates, as described in "Materials and Methods" section. Their survival was tracked to draw Kaplan-Meier survival curves and log-rank test was performed for the statistical comparison between two groups.
